Curative effect of levosimendan combined with dual antiplatelet therapy and its influences on ventricular remodeling, serum soluble growth stimulation expressed gene 2 and N-terminal pro brain natriuretic peptide in elderly patients with heart failure of ischemic cardiomyopathy
10.3760/cma.j.cn101721-20241021-00338
- VernacularTitle:左西孟旦联合双联抗血小板药物治疗老年缺血性心肌病心力衰竭患者的效果
- Author:
Long YAO
1
;
Hao LI
1
;
Jizhong HE
1
Author Information
1. 陕西省延安市人民医院心内科，延安 716000
- Publication Type:Journal Article
- Keywords:
Heart failure;
Ischemic cardiomyopathy;
Levosimendan;
Dual antiplatelet;
Ventricular remodeling
- From:
Clinical Medicine of China
2025;41(5):359-365
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the effect of levosimendan combined with dual antiplatelet therapy on heart failure in elderly patients with ischemic cardiomyopathy and its effect on ventricular remodeling, serum growth stimulating gene 2 protein (sST2) and N-terminal pro-brain natriuretic peptide (NT-proBNP) levels.Methods:A total of 158 elderly patients with ischemic cardiomyopathy admitted to Yan 'an People 's Hospital from December 2021 to December 2023 were selected as the research objects. Under the principle of balanced and comparable baseline characteristics between groups, they were divided into observation group ( n=79) and control group ( n=79) by random number table method. The patients in the control group received dual antiplatelet and conventional treatment, and patients in the observation group were treated with levosimendan on the basis of the treatment plan of the control group. After treatment, the effective rate, left ventricular ejection fraction (LVEF), left ventricular end-diastolic volume (LVEDV), left ventricular end-systolic volume (LVESV), serum sST2 level, NT-proBNP level and the incidence of disease-related adverse reactions after treatment were compared between the two groups. Measurement data with normal distribution were expressed as xˉ± s, and the mean comparison between groups was performed by independent sample t test. Counting data were expressed as case(%), comparison between groups was performed by χ2 test. P<0.05 was considered statistically significant. Results:After treatment, the effective rate of the observation group was 97.47% (77/79), which was significantly higher than 82.28% (65/79) of the control group ( χ2=10.01, P=0.002); at the same time, the LVEF level of the observation group after intervention was (49.26±3.98)%, which was significantly higher than that of the control group (46.13±4.02)%, and the difference was statistically significant ( t=4.92, P<0.001), and the levels of LVEDV and LVESV in the observation group after intervention were (104.25±18.36)mL and (49.24±6.37)mL, respectively, which were significantly lower than (118.97±19.25)mL and (55.12±6.28)mL in the control group, and the differences were statistically significant ( t values were 4.92 and 5.84, respectively; all P<0.01). In addition, the levels of sST2 and NT-proBNP in the observation group after intervention were (37.25±15.48)μg/L and (825.37±86.24)ng/L, respectively, which were significantly lower than those in the control group (66.35±16.37)μg/L and (1136.24±121.75)ng/L, and the differences were statistically significant ( t values were 11.48 and 18.52, respectively; all P<0.001); the total incidence of adverse drug reactions in the observation group and the control group was 17.72% (14/79) and 18.90% (15/79), respectively, and the difference was not statistically significant ( χ2=0.04, P=0.837). Conclusion:The combination of levosimendan and dual antiplatelet therapy can effectively improve the efficacy of ischemic cardiomyopathy in heart failure, improve ventricular remodeling, and regulate sST2 and NT proBNP levels, with high application value.
